Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. (Q27852806)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.	scientific article

Statements

scholarly article

1 reference

PubMed publication ID

13 November 2016

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. (English)

1 reference

PubMed publication ID

13 November 2016

1 reference

based on heuristic

inferred from title

author name string

S-H I Ou

1

0 references

P A Jänne

2

0 references

C H Bartlett

3

0 references

Y Tang

4

0 references

D-W Kim

5

0 references

G A Otterson

6

0 references

L Crinò

7

0 references

P Selaru

8

0 references

D P Cohen

9

0 references

J W Clark

10

0 references

G J Riely

11

0 references

publication date

February 2014

0 references

Annals of Oncology

0 references

25

0 references

2

0 references

415-22

0 references

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27852806&oldid=1622614468"